Related references
Note: Only part of the references are listed.
Article
Multidisciplinary Sciences
Jonas S. Heitmann et al.
Summary: The study showed that CoVac-1 vaccine has a favorable safety profile, inducing broad, potent T cell responses that are independent of SARS-CoV-2 variants, supporting its ongoing evaluation in a phase II trial for patients with B cell or antibody deficiency.
Article
Infectious Diseases
ShengLi Xia et al.
Summary: This study evaluated the safety and immunogenicity of the inactivated COVID-19 vaccine BBIBP-CorV in participants aged 3-17 years. The results showed that BBIBP-CorV was safe and well tolerated at all tested dose levels and induced robust antibody responses. Phase 3 trials are recommended in the population younger than 18 years to further assess its safety and protection efficacy against COVID-19.
LANCET INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
C. Buddy Creech et al.
Summary: The study demonstrated that two 50-mu g doses of the mRNA-1273 vaccine are safe and effective in inducing immune responses and preventing Covid-19 in children aged 6 to 11 years, with noninferior responses compared to young adults.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Natasha M. Clark et al.
Summary: This study found no evidence that antibodies in COVID-19 convalescent plasma (CCP) enhance the infection of SARS-CoV-2. The neutralizing titer of CCP was not affected when Fc receptors were present on target cells, despite the strongest correlation between neutralizing activity and high titers of anti-S IgG antibodies. These findings support the use of currently available antibody-based treatments, including CCP transfusion, as well as prophylactic approaches with different vaccine platforms.
Article
Immunology
Eman Farid et al.
Summary: This study evaluated the level of S antibodies in individuals vaccinated with Sinopharm and found that those with low levels of S antibodies were more likely to have immune-related clinical conditions, particularly in the population above 50 years old. However, the administration of a booster dose of the Pfizer/BioNtech vaccine significantly increased S antibody levels, suggesting the triple dose vaccination strategy as a useful method of ensuring protective immunity against SARS-CoV-2.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Khaled Greish et al.
Summary: This study evaluated the reactogenicity and immunogenicity of the BBIBP-CorV vaccine in children aged 3 to 12. The results showed that the vaccine is safe and well-tolerated in this age group, and can induce an effective immune response and the production of neutralizing antibodies.
Article
Virology
Zhangkai J. Cheng et al.
Summary: By monitoring and analyzing the antibody response in healthy individuals who received a booster injection, this study found that serum antibody levels decrease over time but reach a significant peak after the booster, indicating a recall immune response. Additionally, CyTOF data shows active antibody production and changes in the immune environment.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Medicine, General & Internal
Natasha B. Halasa et al.
Summary: This study found that maternal vaccination with two doses of mRNA vaccine reduced the risk of hospitalization for Covid-19, including critical illness, among infants younger than 6 months of age.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Christos Papaneophytou et al.
Summary: Monitoring IgG antibody levels against SARS-CoV-2 is crucial during the COVID-19 pandemic. A study found that individuals with evidence of prior infection who received mRNA or adenoviral vaccines had higher levels of IgG antibodies against the spike protein compared to unvaccinated individuals with prior infection or individuals without prior infection who received vaccines. Regardless of the vaccine technology, two doses produced strong anti-SARS-CoV-2 IgG responses. Results also indicated that even a single dose of vaccine is sufficient to elicit high levels of antibody response in individuals previously infected with SARS-CoV-2.
Article
Multidisciplinary Sciences
Jaime S. Rosa Duque et al.
Summary: This study compares the immunogenicity and reactogenicity of two widely available SARS-CoV-2 vaccines, BNT162b2 (an mRNA vaccine) and CoronaVac (a whole-virus inactivated vaccine), in healthy adolescents. The results show that the antibody and T cell immune responses in adolescents receiving two doses of either BNT162b2 or CoronaVac are similar to those seen in adults receiving two doses of the same vaccine. However, the immune response to a single dose of BNT162b2 in adolescents is not as robust. Additionally, CoronaVac induces a higher proportion of adolescents to have positive antibody responses compared to adults. Adverse reactions are generally mild for both vaccines, with BNT162b2 having slightly more frequent adverse reactions.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Caroline G. Atyeo et al.
Summary: Pregnant individuals infected with SARS-CoV-2 are at high risk of complications, but little is known about the immune response and antibody transfer from COVID-19 vaccines in different trimesters. This study characterizes the antibody response and transplacental transfer in pregnant individuals who received Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. The findings show differences in vaccine-induced functions, receptor-binding, and efficacy against variants of concern. First and third trimester vaccination enhances maternal immune response and antibody transfer compared to the second trimester. These results provide valuable insights into the effect of vaccine platform and timing on maternal immune response and transplacental antibody transfer.
NATURE COMMUNICATIONS
(2022)
Article
Virology
Yasmine Gaber et al.
Summary: This study evaluated the correlation between neutralizing antibodies (NAbs) and anti-SARS-CoV-2 IgG/total Ig antibodies in asymptomatic and previously symptomatic SARS-CoV-2 patients. The results showed that both groups had NAbs, with higher titers in previously symptomatic patients. There was a correlation between NAbs and anti-SARS-CoV-2 IgG/total Ig antibodies, which can be used to estimate the presence of protective immunity.
Article
Virology
Yunfei Wang et al.
Summary: The S1 domain of SARS-CoV-2 induces higher levels of antibodies in mice and efficiently neutralizes the virus when adjuvanted with alum. Research suggests that expression systems with posttranslational modification abilities and adjuvants prone to a Th1 response are crucial for effective COVID-19 vaccines.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Virology
Wei Zhou et al.
Summary: This study observed significant decline in IgM and IgG antibodies in COVID-19 patients between weeks 4 to 10 after symptom onset. Notably, 77.5% of patients experienced a rapid reduction by half in IgG levels within the second month. Furthermore, in the recovery stage, IgG levels decreased significantly by a median of 50%.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Pharmacology & Pharmacy
Xiaoni Cui et al.
Summary: Following the outbreak of COVID-19 caused by SARS-CoV-2 in December 2019, vaccines based on four major strategies have entered emergency use authorization and pre-certification evaluation. More than 4 million people worldwide have died from COVID-19 in 2021, highlighting the urgent need for safe and effective vaccines to restore normal economic and social activities. The current review not only summarizes existing COVID-19 vaccines but also looks ahead to the development of additional vaccines in the future.
DRUG DISCOVERIES AND THERAPEUTICS
(2021)
Review
Microbiology
Swapnil B. Kadam et al.
Summary: The outbreak of COVID-19 marked the third spillover of an animal coronavirus to humans in the last 20 years, likely originating from bats and possibly transmitted to humans via unknown intermediate host (potentially a pangolin). The causative pathogen, SARS-CoV-2, shares genetic similarities with bat and pangolin coronaviruses in terms of protein structure and genome, suggesting a zoonotic origin.
JOURNAL OF BASIC MICROBIOLOGY
(2021)
Article
Immunology
Qiu-Yan Xu et al.
Summary: An urgent need for a highly protective vaccine against COVID-19 exists. This study evaluated the response and duration of 5 subsets of anti-SARS-CoV-2 antibodies post-vaccination, and found intense but decaying antibody response with the CoronaVac vaccine, suggesting the need for booster doses in vaccine strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Microbiology
Yoshitomo Morinaga et al.
Summary: This study shows that the CRNT and commercial anti-RBD antibody test can effectively differentiate convalescent COVID-19 patients. Strong positive results with the anti-RBD antibody test can reflect neutralizing activity against emerging variants, indicating potential for monitoring functional immunity against wild and variant-type viruses in the clinical laboratory.
MICROBIOLOGY SPECTRUM
(2021)
Review
Biochemistry & Molecular Biology
Long Min et al.
Summary: Following the outbreak of the pandemic, the development of neutralizing antibodies and vaccines targeting the coronavirus has become crucial, with RBD being identified as the key research target.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Dongfu Jin et al.
Summary: SARS-CoV-2, a novel beta-coronavirus, has rapidly spread as a pandemic since 2020, causing over 100 million deaths worldwide. Neutralizing monoclonal antibodies targeting the S protein have become a key focus in current research and treatment strategies.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Mine Durusu Tanriover et al.
Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.
Article
Infectious Diseases
Bihua Han et al.
Summary: The study evaluated the safety, tolerability, and immunogenicity of the candidate COVID-19 vaccine CoronaVac containing inactivated SARS-CoV-2 in children and adolescents aged 3-17 years. The research findings indicate that the 3.0 μg dose induced higher levels of neutralizing antibodies compared to the 1.5 μg dose, supporting the use of the 3.0 μg dose for further studies in this age group.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Robert W. Frenck et al.
Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Bruna Lo Sasso et al.
Summary: The study demonstrates an effective antibody response post-vaccination, with variations in antibody levels among different vaccinated groups, and higher antibody levels observed in females.
Article
Medicine, Research & Experimental
Ofer Beharier et al.
Summary: The study demonstrates that the BNT162b2 mRNA vaccine induces a strong maternal IgG response that crosses the placenta barrier to reach fetal titers within 15 days of the first dose. The transfer ratio of anti-COVID-19 antibodies from mother to neonate differs between vaccination and infection groups, with lower IgG transfer ratio for third-trimester compared to second-trimester infection. Additionally, fetal IgM response was only detected in neonates from the infected group.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Immunology
Stuart P. Weisberg et al.
Summary: This study found distinct antibody responses in children and adults after SARS-CoV-2 infection. Adult COVID-19 cohorts showed a broader range of antibody responses, while children predominantly generated antibodies specific for the S protein and had reduced neutralizing activity compared to adults.
Review
Pediatrics
Jonas F. Ludvigsson
Review
Allergy
Ahmet Kursat Azkur et al.
Review
Public, Environmental & Occupational Health
Alfonso J. Rodriguez-Morales et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2020)
Review
Pediatrics
Riccardo Castagnoli et al.
Letter
Medicine, General & Internal
Xiaoxia Lu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Medicine, General & Internal
Elizabeth Whittaker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Article
Medicine, General & Internal
Leora R. Feldstein et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
